Outcome of Board Meeting held on 26 May, 2026
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.7 pts more than Nifty Microcap 250 and 15.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma Ltd reported strong audited financial results for FY2026 ended March 31, 2026. Standalone revenue from operations grew 14.2% to Rs. 13,414.76 million from Rs. 11,743.74 million. Consolidated revenue grew 12.5% to Rs. 29,509.38 million from Rs. 26,228.45 million. Standalone PAT jumped 59.7% to Rs. 3,006.98 million from Rs. 1,882.72 million. Consolidated PAT rose 9.8% to Rs. 4,200.64 million from Rs. 3,826.19 million. The Board recommended a final dividend of Rs. 0.90 per equity share (90%) for FY2025-26, subject to shareholder approval. Statutory auditors MSKA & Associates LLP issued unmodified opinions on both standalone and consolidated results. The company also incorporated two new wholly owned subsidiaries in Europe and Canada during the year.
The results demonstrate robust profitability growth with significant PAT expansion on standalone basis. Strong cash generation from operations and an unmodified audit opinion are positive signals for investors. The 90% dividend payout reinforces shareholder returns amid operational growth.